Cited by 793Blood Pressure and Hypertension StudiesRenal and Vascular PathologiesHormonal Regulation and Hypertension

Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial

Kandzari, David E, Böhm, Michael, Mahfoud, Felix, Townsend, Raymond R, Weber, Michael A, Pocock, Stuart, Tsioufis, Konstantinos, Tousoulis, Dimitrios +57 more·2018·The Lancet

Abstract

Background Previous catheter-based renal denervation studies have reported variable efficacy results. We aimed to evaluate safety and blood pressure response after renal denervation or sham control in patients with uncontrolled hypertension on antihypertensive medications with drug adherence testing.Methods In this international, randomised, single-blind, sham-control, proof-of-concept trial, patients with uncontrolled hypertension (aged 20-80 years) were enrolled at 25 centres in the USA, Germany, Japan, UK, Australia, Austria, and Greece. Eligible patients had an office systolic blood pressure of between 150 mm Hg and 180 mm Hg and a diastolic blood pressure of 90 mm Hg or higher; a 24 h ambulatory systolic blood pressure of between 140 mm Hg and 170 mm Hg at second screening; and were on one to three antihypertensive drugs with stable doses for at least 6 weeks. Patients underwent renal angiography and were randomly assigned to undergo renal denervation or sham control. Patients, caregivers, and those assessing blood pressure were masked to randomisation assignments. The primary efficacy endpoint was blood pressure change from baseline (measured at screening visit two), based on ambulatory blood pressure measurements assessed at 6 months, as compared between treatment groups. Drug surveillance was used to assess medication adherence. The primary analysis was done in the intention-to-treat population. Safety events were assessed through 6 months as per major adverse events. This trial is registered with ClinicalTrials.gov, number NCT02439775, and follow-up is ongoing.Findings Between July 22, 2015, and June 14, 2017, 467 patients were screened and enrolled. This analysis presents results for the first 80 patients randomly assigned to renal denervation (n=38) and sham control (n=42). Office and 24 h ambulatory blood pressure decreased significantly from baseline to 6 months in the renal denervation group (mean baseline-adjusted treatment differences in 24 h systolic blood pressure -7·0 mm Hg, 95% CI -12·0 to -2·1; p=0·0059, 24 h diastolic blood pressure -4·3 mm Hg, -7·8 to -0·8; p=0.0174, office systolic blood pressure -6·6 mm Hg, -12·4 to -0·9; p=0·0250, and office diastolic blood pressure -4·2 mm Hg, -7·7 to -0·7; p=0·0190). The change in blood pressure was significantly greater at 6 months in the renal denervation group than the sham-control group for office systolic blood pressure (difference -6·8 mm Hg, 95% CI -12·5 to -1·1; p=0·0205), 24 h systolic blood pressure (difference -7·4 mm Hg, -12·5 to -2·3; p=0·0051), office diastolic blood pressure (difference -3·5 mm Hg, -7·0 to -0·0; p=0·0478), and 24 h diastolic blood pressure (difference -4·1 mm Hg, -7·8 to -0·4; p=0·0292). Evaluation of hourly changes in 24 h systolic blood pressure and diastolic blood pressure showed blood pressure reduction throughout 24 h for the renal denervation group. 3 month blood pressure reductions were not significantly different between groups. Medication adherence was about 60% and varied for individual patients throughout the study. No major adverse events were recorded in either group.Interpretation Renal denervation in the main renal arteries and branches significantly reduced blood pressure compared with sham control with no major safety events. Incomplete medication adherence was common.Funding Medtronic.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)30951-6

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In patients receiving medical treatment for moderate, uncontrolled hypertension, renal denervation extending into branch arteries caused significant, clinically relevant reductions in blood pressure compared with sham controls.

    “A study of patients receiving medical treatment for moderate, uncontrolled hypertension indicated that RDN extending into branch arteries caused significant, clinically relevant reductions in BP compared with sham controls168.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 11

  1. (DENERHTN): A multicentre, open-label, randomised controlled trial. Lancet 2015; 385 : 528
  2. 2 Trial): A randomised controlled trial. Lancet 2010; 376 : 1903-9. 534
  3. - 2017; 390 : 2160-70. 538
  4. Hypertension (DENERHTN) Trial. Circulation 2016; 134 : 847-57. 541
  5. SYMPLICITY HTN-3 trial. Eur Heart J 2015; 36 : 219-27. 543
  6. J 2016; 171 : 82-91. 547
  7. - 2012; 25 : 568-75. 555
  8. Eighth Joint National Committee (JNC 8). JAMA 2014; 311 : 507-20. 586
  9. Cardiology (ESC). J Hypertens 2013; 31 : 1281-357. 590
  10. Cardiol 2017; 2 : 775-81. 599
  11. Circulation 2003; 107 : 1401-6.

Cited by

Sorted by citations

Authors
Kandzari, D. E., Böhm, M., Mahfoud, F., Townsend, R. R., Weber, M. A., Pocock, S., Tsioufis, K., Tousoulis, D., Choi, J. W., East, C., Brar, S., Cohen, S. A., Fahy, M., Pilcher, G., Kario, K., Aoki, J., Batson, B., Böhm, M., Choi, J. W., Cohen, D. L., Dangas, G., David, S., Davies, J., Devireddy, C. M., Kandzari, D., Kario, K., Lee, D. P., Lurz, P. C., Papademetriou, V., Patel, M., Patel, K., Schmieder, R. E., Sharp, A. S. P., Singh, J., Tsioufis, K., Walton, A., Weber, T., Weil, J., Zeller, T., Ziada, K., Tanabe, K., Wilkins, R., Mahfoud, F., East, C., Wilensky, R., Contreras, J., Steigerwalt, S., Chapman, N., Lea, J. P., Reedus, D., Hoshide, S., Ma, A., Fengler, K., Li, P., Svetkey, L., Rao, A., Schmid, A., Watkinson, A. F., Brown, A., Tousoulis, D., Hopper, I., Suppan, M., Agdirlioglu, T., Noory, E., & Chasen, C.
Affiliations
  • Piedmont Atlanta Hospital (US)
  • University of Pennsylvania (US)
  • SUNY Downstate Health Sciences University (US)
  • London School of Hygiene & Tropical Medicine (GB)
  • National and Kapodistrian University of Athens (GR)
Corresponding author
  • Kandzari, David E
  • Kandzari, David
Venue
The Lancet
Publisher
Elsevier BV
Published
2018-06
Volume
391
Issue
10137
Pages
2346-2355
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2804838656
Cited by
793
References
37
Citations by year
2026: 51 · 2025: 52 · 2024: 86 · 2023: 100 · 2022: 115 · 2021: 111 · 2020: 110 · 2019: 124 · 2018: 42 · 2017: 1
FWCI
72.89
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
Funders
  • Deutsche Hochdruckliga
  • Medtronic
  • Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung.
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal and Vascular Pathologies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
Keywords
renal denervation, uncontrolled hypertension, antihypertensive drugs, medication adherence, blood pressure reduction, ambulatory blood pressure, renal sympathetic nerves, treatment safety, major adverse events, catheter ablation, renin-angiotensin system, renin-angiotensin-aldosterone system, renin
MeSH terms
Angiography, Antihypertensive Agents, Blood Pressure, Denervation, Female, Humans, Hypertension, Kidney, Male, Middle Aged, Renal Artery, Single-Blind Method, Treatment Outcome, Blood Pressure Monitoring, Ambulatory, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review